Applied Biosystems/MDS SCIEX Announces New Proteomics Tools for Biomarker Research.New Instrument System and Software Enable More in-Depth Study of Emerging Area of Scientific Study FOSTER CITY, Calif. -- Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. (NYSE NYSE See: New York Stock Exchange : ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ), an Applera Corporation business, and its joint venture partner, Sciex, a division of MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Inc.'s Analytical Technologies business, (NYSE:MDZ MDZ Mendez MDZ Moskauer Deutsche Zeitung (Moscow German newspaper) MDZ Maritime Defense Zone MDZ Musik Der Zukunft (music label & community) MDZ Mendoza, Mendoza, Argentina - El Plumerillo , TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :MDS), today announced a new instrument system and software designed to assist the growing number of life scientists involved in biomarker research. An updated release of the Applied Biosystems/MDS SCIEX 4800 MALDI MALDI Matrix-Assisted Laser Desorption/Ionization TOF/TOF[TM] mass spectrometer and enhancements to ProteinPilot[TM] software, which augments the performance of the 4800 Plus, is expected to help scientists gain deeper quantitative insight into the study of proteomics. The study of protein biomarkers is important to life scientists because the identification of biomarkers can indicate the presence and progression of a variety of diseases or response to drugs. Central to this research is the science of proteomics through which thousands of proteins in a biological sample - e.g. tissues, cells, serum, urine, cerebrospinal fluid cerebrospinal fluid (CSF) Clear, colourless liquid that surrounds the brain and spinal cord and fills the spaces in them. It helps support the brain, acts as a lubricant, maintains pressure in the skull, and cushions shocks. - can be analyzed in the same experiment to obtain a snapshot of the proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. . To discover new biomarker candidates, these snapshots need to be compared quantitatively against other samples, such as healthy versus diseased samples, so the complex differences that exist in biological systems can be found and exploited. The discovery of protein biomarkers requires large numbers of sample sets and simplified data output produced on proteomics research platforms. Much biomarker research is conducted by biological scientists who are not necessarily proteomics experts. The new advancements from Applied Biosystems/MDS SCIEX are designed to enable non-expert instrument users to achieve higher throughput sample processing, greater depth of proteome coverage, greater statistical rigor rigor /rig·or/ (rig´er) [L.] chill; rigidity. rigor mor´tis the stiffening of a dead body accompanying depletion of adenosine triphosphate in the muscle fibers. , more confident protein detection, and better quantitative results. Earlier versions of some of these products are helping translational medicine translational medicine Molecular medicine The constellation of activities which seek to translate the science of gene discovery, gene transfer, and functional genomics into gene-targeted therapies researchers at Cornell University Cornell University, mainly at Ithaca, N.Y.; with land-grant, state, and private support; coeducational; chartered 1865, opened 1868. It was named for Ezra Cornell, who donated $500,000 and a tract of land. With the help of state senator Andrew D. complete a biomarker study of Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Utilizing proteomics products from Applied Biosystems/MDS SCIEX, the study identified 23 biomarker candidates that were associated with the presence of Alzheimer's disease and may provide links to the pathological mechanisms of the disease. The scientists involved in the study cited the discovery as a potential breakthrough. Currently, there are no definitive tests available for the diagnosis of the disease in living subjects, with confirmation of its existence normally being made after the death of a patient. "We set out to better diagnose Alzheimer's disease, and the Applied Biosystems/MDS SCIEX joint venture provided powerful proteomics tools to help identify the biomarker candidates from cerebrospinal fluid," said Kelvin Lee, a Cornell professor of chemical and biomolecular engineering. "Our research uncovered new candidate biomarkers as a first step. The next step in biomarker research is to validate what we found as relevant, so it may someday translate into a real advancement in the medical treatment of Alzheimer's disease." New Proteomic Tools The new proteomics tools from Applied Biosystems/MDS SCIEX joint venture include: * The 4800 Plus MALDI TOF/TOF[TM] Analyzer - This system is a proteomics analyzer that can identify thousands of proteins in a biological sample. The enhancements from the previous version of the system provide an improved platform to better support the larger sample studies that proteomics researchers are moving towards, especially for biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. . * New version of ProteinPilot[TM] Software -ProteinPilot software is designed to maximize the information that can be obtained from the combination of the 4800 Plus and Applied Biosystems iTRAQ[R] reagents. It delivers more accurate protein detection, easier manageability and broader support for quantitation, thereby providing greater confidence in the results. These latest tools are designed to be compatible with the future commercial release of the 8-plex version of Applied Biosystems iTRAQ reagents, a labeling chemistry allowing scientists and biologists to quantitatively compare proteins between samples. The 8-plex version of these reagents is expected to increase the number of samples that can be compared simultaneously, providing higher throughput, better accuracy and greater statistical confidence in research results. "Biomarker research has the potential to change the face of healthcare," said Laura Lauman, president for Applied Biosystems' proteomics and small molecule division. "The latest enhancements of our portfolio provide powerful tools that deliver higher throughput for analyzing more samples and identifying higher quality biomarker candidates." The Applied Biosystems/MDS SCIEX Instruments joint venture, which has existed for the past 20 years between Applied Biosystems and MDS Inc., continues to expand its broad portfolio of mass spectrometry-based technologies and systems that enable new advancements in research laboratories in biotechnology, biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. and pharmaceutical fields. "Sciex and Applied Biosystems are playing a leadership role in enabling more advanced research by our development of these innovative and reliable tools in the growing area of biomarker research," said Andy Boorn, president for MDS Analytical Technologies. "We are committed to delivering the right combination of instruments and software to help move the biomarker research forward by facilitating the integration of the scientists' efforts." About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. (DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic ), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing paternity testing see parentage testing. ); biosecurity, which refers to products needed in response to the threat of biological terrorism Noun 1. biological terrorism - terrorism using the weapons of biological warfare bioterrorism act of terrorism, terrorism, terrorist act - the calculated use of violence (or the threat of violence) against civilians in order to attain goals that are and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.9 billion during fiscal 2006. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com. About MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 6,200 highly skilled people in 28 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day. About MDS SCIEX Sciex is a division of MDS Analytical Technologies. The Sciex product portfolio offers proven market leadership in mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. through its joint ventures with two of the world's leading analytical instrumentation and life sciences companies, Applied Biosystems, a business of the Applera Corporation and PerkinElmer Inc. Find out more at www.mdssciex.com Applied Biosystems Forward Looking Statements Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should," "expect," and "planned," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. Footnote: 1 A published study in the Annals of Neurology Applied Biosystems, AB (Design), Applera and Celera are registered trademarks and iTRAQ is a trademark of Applera Corporation or its subsidiaries in the US and/or certain other countries. MALDI TOF/TOF and ProteinPilot are trademarks of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc. Copyright[c] 2007. Applera Corporation and MDS Inc. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion